Stephanie Davis
Stock Analyst at Barclays
(0.93)
# 3,630
Out of 4,732 analysts
101
Total ratings
27.69%
Success rate
-19.41%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $4.81 | +4.06% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $53.72 | +39.61% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.99 | -12.39% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.57 | +31.29% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $10.00 | +90.00% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $242.05 | +19.81% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $22.43 | +7.00% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $126.27 | +5.33% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $42.57 | +36.25% | 2 | Oct 31, 2024 | |
| TALK Talkspace | Maintains: Equal-Weight | $2 → $3 | $3.02 | -0.66% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $154 → $168 | $151.20 | +11.11% | 3 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $1.21 | -37.76% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5.5 → $5 | $6.89 | -27.43% | 10 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $238.56 | +4.38% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $37.47 | -35.95% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $27.21 | +6.58% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $9.09 | +274.04% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $21.00 | +61.90% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $216.59 | +7.58% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $5.49 | +209.65% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $102.42 | -25.80% | 5 | Jun 7, 2022 |
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $4.81
Upside: +4.06%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $53.72
Upside: +39.61%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.99
Upside: -12.39%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.57
Upside: +31.29%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $10.00
Upside: +90.00%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $242.05
Upside: +19.81%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.43
Upside: +7.00%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $126.27
Upside: +5.33%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $42.57
Upside: +36.25%
Talkspace
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.02
Upside: -0.66%
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $154 → $168
Current: $151.20
Upside: +11.11%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $1.21
Upside: -37.76%
Oct 9, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $5
Current: $6.89
Upside: -27.43%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $238.56
Upside: +4.38%
Jul 2, 2024
Initiates: Overweight
Price Target: $24
Current: $37.47
Upside: -35.95%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $27.21
Upside: +6.58%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $9.09
Upside: +274.04%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $21.00
Upside: +61.90%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $216.59
Upside: +7.58%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $5.49
Upside: +209.65%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $102.42
Upside: -25.80%